Page 7; "Removes need for expensive Phase 3 trials"
This means three things to me:
1) RGS will be in the Japanese (any other country to allow it?) market years earlier, generating profits.
2) The profits made will help pay for those "expensive Phase 3 trials" in Europe and the US. Thereby eliminating predatory JV overtures, and/0r lessening the impact of an equity raising's dilution.
3) Perhaps -- pure speculation -- positive and safe results on a large scale from the Japanese market will prompt the FDA to designate RGS with "Fasttrack," or "Breakthrough." Lowering capital required, while speeding up its approval in Europe and the US.
OV
RGS Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
